Alexion Pharmaceuticals Inc. | Key People and Executives
Ludwig N. Hantson
Chief Executive Officer & Director
David Richard Brennan
Chairman
Judith A. Reinsdorf
Independent Director
Deborah L. Dunsire
Independent Director
Francois Nader
Independent Director
Paul A. Friedman
Independent Director
Felix James Baker
Independent Director
Christopher J. Coughlin
Independent Director
John T. Mollen
Independent Director
Ann Margaret Veneman
Independent Director
Andreas Rummelt
Independent Director
Ludwig N. Hantson
Chief Executive Officer & Director
John J. Orloff
Executive VP & Head-Research & Development
Indrani M. Franchini
Chief Compliance Officer & Executive VP
Brian Goff
Chief Commercial Officer
John V. W. Reynders
Vice President-R&D Bioinformatics
Daniel A. Bazarko
Chief Accounting Officer & Senior Vice President
Susan Altschuller
Vice President-Investor Relations
Rana Strellis
Senior Vice President-Communications & Culture
Anne-Marie Law
Chief Human Resource Officer & Executive VP
Michael V. Greco
Secretary & Senior Vice President-Law
Douglas J. Barry
Vice President-Corporate Law
Ellen V. Chiniara
Executive Vice President & General Counsel
David Richard Brennan
Chairman
Judith A. Reinsdorf
Independent Director
Deborah L. Dunsire
Independent Director
Francois Nader
Independent Director
Paul A. Friedman
Independent Director
Felix James Baker
Independent Director
Christopher J. Coughlin
Independent Director
John T. Mollen
Independent Director
Ann Margaret Veneman
Independent Director
Andreas Rummelt
Independent Director
| Address |
121 Seaport Boulevard
Boston Massachusetts 02210
United States
|
|
Employees
|
- |
| Website |
http://www.alexion.com |
| Updated |
07/08/2019 |
| Alexion Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on serving patients with devastating and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products. Its products include soliris, strensiq and kanuma. The company was founded by Joseph A. |
